Martin Patricia A. 4

What Happened
Patricia A. Martin, a director of AN2 Therapeutics, was issued 766 shares of the company's common stock on July 10, 2026. The shares were reported as an award/acquisition at $0.00 per share (total reported value $0) and represent equity issued in lieu of cash director compensation. All shares vest immediately.

Key Details

• Transaction date: 2026-07-10; transaction code: A (award/grant or other acquisition).
• Shares issued/acquired: 766 shares at $0.00 per share (total $0 reported).
• Shares owned after transaction: Not disclosed in this Form 4 filing.
• Footnote: F1 — shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy; all shares vest immediately.
• Filing timeliness: Form 4 filed with the SEC on 2026-07-10 (same reporting date).

Context
This was a director compensation award, not an open-market purchase or sale. Such equity issued in lieu of cash is a routine form of non-employee director pay and does not by itself indicate insider buying or selling sentiment. Immediate vesting means the shares are not subject to a vesting schedule and could be sold, but the filing does not show any sale or other disposition.